Literature DB >> 7806825

Duodenal gastrinoma: the solution to the pancreatic paradox.

I M Modlin, G P Lawton.   

Abstract

There has been a recent focus of attention on the duodenum as a major source of gastrinomas. The question has often arisen as to why the pancreas should give rise to gastrinomas because, in the adult, it contains no gastrin-producing (G) cells. However, the numerous G cells of the duodenum may proliferate and function as a "carcinoid" lesion, producing a relatively indolent tumor, much like a papillary carcinoma of the thyroid. On the contrary, islet cells of the pancreas, which do not produce gastrin, may behave much like a neuroendocrine carcinoma and may be defined as a "pancreatic gastrinoma" because they produce an ectopic hormone (gastrin). These lesions are capable of behaving much more aggressively, as do many other ectopic hormone-producing neoplasms. The recognition of the difference between these two types of gastrinoma is of considerable clinical and biological significance.

Entities:  

Mesh:

Year:  1994        PMID: 7806825     DOI: 10.1097/00004836-199410000-00002

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  4 in total

Review 1.  Imaging of neuroendocrine tumors of the pancreas.

Authors:  J L Fidler; C D Johnson
Journal:  Int J Gastrointest Cancer       Date:  2001

2.  Zollinger-Ellison syndrome associated with neurofibromatosis type 1: a case report.

Authors:  Wan-Sik Lee; Yang-Seok Koh; Jung-Chul Kim; Chang-Hwan Park; Young-Eun Joo; Hyun-Soo Kim; Chol-Kyoon Cho; Sung-Kyu Choi; Jong-Sun Rew; Sei-Jong Kim
Journal:  BMC Cancer       Date:  2005-07-21       Impact factor: 4.430

3.  Zollinger-Ellison syndrome: Revelation of the gastrinoma triangle.

Authors:  Rong-Hsin Yang; Yum-Kung Chu
Journal:  Radiol Case Rep       Date:  2015-12-03

Review 4.  Surgical management of pancreatico-duodenal tumors in multiple endocrine neoplasia syndrome type 1.

Authors:  Göran Akerström; Peter Stålberg; Per Hellman
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.